Search

Displaying results 2321 - 2330 of 8196 in total
  1. Drug

    Quinidine

    go.drugbank.com/drugs/DB00908
    Approved

    This alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication. … Quinidine is a D-isomer of [quinine] present in the bark of the Cinchona tree and similar plant species.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  2. Drug

    Pasireotide

    go.drugbank.com/drugs/DB06663
    ApprovedInvestigational

    Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease.

    Synonyms: cyclo((4R)-4-(2-aminoethylcarbamoyloxy)-L-prolyl-L-phenylglycyl-D-tryptophyl-L-lysyl-4-O-benzyl-L-tyrosyl-L- phenylalanyl-)Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors
  3. Drug

    Ponatinib

    go.drugbank.com/drugs/DB08901
    ApprovedInvestigational

    Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  4. Target

    Very-long-chain 3-oxoacyl-CoA reductase

    go.drugbank.com/bio_entities/BE0014905
    EnzymeHumans

    Catalyzes the second of the four reactions of the long-chain fatty acids elongation cycle. This endoplasmic reticulum-bound enzymatic process, allows the addition of two carbons to the chain of long- and very long-chain fatty acids/VLCFA...

    Synonyms: KAR
  5. Drug

    Enlonstobart

    go.drugbank.com/drugs/DB21890
    Investigational

    [A274486] It targets the programmed cell death protein 1 (PD-1), is being developed by the CSPC Pharmaceutical Group for the treatment of advanced cervical cancer and other solid tumours.

  6. Drug

    Zidovudine

    go.drugbank.com/drugs/DB00495
    ApprovedInvestigational

    A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group.

    Mixtures: ZOVILAM PED DT®Categories: Cytochrome P-450 Substrates, P-glycoprotein substrates
  7. Drug

    Gepirone

    go.drugbank.com/drugs/DB12184
    Approved

    Although earlier clinical trials showed promising results for gepirone, its formulation as an immediate-release tablet necessitates frequent administration due to the short half-lives. … Gepirone, an azapirone, is a pharmacologic analog of [buspirone] that acts selectively on the pre- and post-synaptic 5HT<sub>1A</sub> receptors.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  8. Drug

    Metrizoic acid

    go.drugbank.com/drugs/DB09346
    Approved

    It present a higher risk of allergic reactions due to its high osmolality. Its approval has been discontinued by the FDA.

  9. Drug

    Arotinolol

    go.drugbank.com/drugs/DB09204
    Investigational

    Arotinolol is an alpha- and beta-receptor blocker developed in Japan. It is a thiopropanolamine with a tertiary butyl moiety. It has been studied for its potential to be an antihypertensive therapy.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  10. Drug

    Baxdrostat

    go.drugbank.com/drugs/DB19090
    ApprovedInvestigational

    due to non-selective steroidal activities [A275513, A275514]. … Baxdrostat is an orally bioavailable, highly selective, first-in-class small-molecule aldosterone synthase inhibitor (ASI) designed to block the production of aldosterone [A275512].

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates